ArticleArchives of microbiology2026
Improvement of cannabichromenic acid synthase activity and construction of recombinant yeast strain.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cannabichromenic acid synthase (CBCAS) catalyzes a pivotal step in the biosynthesis of cannabichromene (CBC), and its activity level directly affects the production of CBC. In this study, a combined approach involving molecular docking and site-directed mutagenesis was employed to engineer the enzyme, with the goal of generating CBCAS variants that exhibit increased catalytic activity. The CBCAS gene was cloned from a cannabis cultivar with a high CBC content. The three-dimensional structure of the CBCAS protein was predicted using AlphaFold2. Molecular docking between the enzyme and its substrate, cannabigerolic acid (CBGA), was performed using Discovery Studio software. Mutation sites predicted to increase substrate binding affinity were identified, and the resulting recombinant plasmids were constructed and transformed into Pichia pastoris (P. pastoris) to generate engineered strains with increased CBCAS activity. Molecular docking analysis revealed that the CBCAS
Indexed as
Identifiers
42250120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.